{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:38Z","timestamp":1792787918947,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40265-026-02381-3","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:40:30Z","timestamp":1788244830000},"page":"1705-1721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma Biomarker Effects of Oral Valiltramiprosate\/ALZ-801 in Early Alzheimer\u2019s Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes"],"prefix":"10.1007","volume":"86","clinical-trial-number":[{"clinical-trial-number":"nct04770220","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04693520","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5104-6231","authenticated-orcid":false,"given":"John A.","family":"Hey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Abushakra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Power","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Porsteinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emer","family":"MacSweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Boada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Murali","family":"Doraiswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny M.","family":"Elahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Rissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Earvin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Flint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elitza","family":"Hristova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kesslak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"McLaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adem","family":"Albayrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean F.","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Tolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"2381_CR1","doi-asserted-by":"publisher","unstructured":"Alzheimer\u2019s Association. 2026 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2026; 22(4):e71345. https:\/\/doi.org\/10.1002\/alz.71345.","DOI":"10.1002\/alz.71345"},{"issue":"5123","key":"2381_CR2","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261(5123):921\u20133. https:\/\/doi.org\/10.1126\/science.8346443.","journal-title":"Science"},{"issue":"1","key":"2381_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000334607","volume":"38","author":"A Ward","year":"2012","unstructured":"Ward A, Crean S, Mercaldi CJ, Collins JM, Boyd D, Cook MN, et al. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4\/4) among patients diagnosed with Alzheimer\u2019s disease: a systematic review and meta-analysis. Neuroepidemiology. 2012;38(1):1\u201313. https:\/\/doi.org\/10.1159\/000334607.","journal-title":"Neuroepidemiology"},{"issue":"1","key":"2381_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12117","volume":"6","author":"S Abushakra","year":"2020","unstructured":"Abushakra S, Porsteinsson AP, Sabbagh M, Bracoud L, Schaerer J, Power A, et al. APOE \u03b54\/\u03b54 homozygotes with early Alzheimer\u2019s disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline. Alzheimers Dement (NY). 2020;6(1):e12117. https:\/\/doi.org\/10.1002\/trc2.12117.","journal-title":"Alzheimers Dement (NY)."},{"issue":"5","key":"2381_CR5","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41591-024-02931-w","volume":"30","author":"J Fortea","year":"2024","unstructured":"Fortea J, Pegueroles J, Alcolea D, Belbin O, Dols-Icardo O, Vaqu\u00e9-Alc\u00e1zar L, et al. APOE4 homozygosity represents a distinct genetic form of Alzheimer\u2019s disease. Nat Med. 2024;30(5):1284\u201391. https:\/\/doi.org\/10.1038\/s41591-024-02931-w.","journal-title":"Nat Med"},{"issue":"2","key":"2381_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70083","volume":"11","author":"S Teipel","year":"2025","unstructured":"Teipel S, Tang Y, Khachaturian A. Clinical efficacy of anti\u2010amyloid antibodies in apolipoprotein E \u03b54 homozygotes: a Bayesian reanalysis of lecanemab and donanemab phase 3 results. Alzheimers Dement (N Y). 2025;11(2):e70083. https:\/\/doi.org\/10.1002\/trc2.70083.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"8","key":"2381_CR7","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup. Alzheimers Dement. 2024;20(8):5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"2381_CR8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat Aging. 2023;3(5):506\u201319. https:\/\/doi.org\/10.1038\/s43587-023-00403-3.","journal-title":"Nat Aging"},{"issue":"5","key":"2381_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422\u201333. https:\/\/doi.org\/10.1016\/S1474-4422(20)30071-5.","journal-title":"Lancet Neurol"},{"issue":"9","key":"2381_CR10","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-022-01925-w","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0 M, Ashton NJ, Shekari M, Salvad\u00f3 G, Ortiz-Romero P, Montoliu-Gaya L, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2022;28(9):1797\u2013801. https:\/\/doi.org\/10.1038\/s41591-022-01925-w.","journal-title":"Nat Med"},{"issue":"11","key":"2381_CR11","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/s43587-025-00951-w","volume":"5","author":"L Montoliu-Gaya","year":"2025","unstructured":"Montoliu-Gaya L, Salvad\u00f3 G, Therriault J, Nilsson J, Janelidze S, Weiner S, et al. Plasma tau biomarkers for biological staging of Alzheimer\u2019s disease. Nat Aging. 2025;5(11):2297\u2013308. https:\/\/doi.org\/10.1038\/s43587-025-00951-w.","journal-title":"Nat Aging"},{"issue":"6","key":"2381_CR12","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K, Alzheimer\u2019s Disease Neuroimaging Initiative, et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27(6):1034\u201342. https:\/\/doi.org\/10.1038\/s41591-021-01348-z.","journal-title":"Nat Med"},{"issue":"11","key":"2381_CR13","doi-asserted-by":"publisher","first-page":"8074","DOI":"10.1002\/alz.14315","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler SE, Petersen KK, Saef B, Tosun D, Shaw LM, Zetterberg H, et al. Head-to-head comparison of leading blood tests for Alzheimer\u2019s disease pathology. Alzheimers Dement. 2024;20(11):8074\u201396. https:\/\/doi.org\/10.1002\/alz.14315.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"2381_CR14","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/alz.13542","volume":"20","author":"RA Rissman","year":"2024","unstructured":"Rissman RA, Langford O, Raman R, Donohue MC, Abdel-Latif S, Meyer MR, et al. Plasma A\u03b242\/A\u03b240 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2024;20(2):1214\u201324. https:\/\/doi.org\/10.1002\/alz.13542.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"2381_CR15","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","volume":"79","author":"MJ Pontecorvo","year":"2022","unstructured":"Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, et al. Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79(12):1250\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2022.3392.","journal-title":"JAMA Neurol"},{"issue":"3","key":"2381_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","volume":"57","author":"JA Hey","year":"2018","unstructured":"Hey JA, Yu JY, Versavel M, Abushakra S, Kocis P, Power A, et al. Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer\u2019s disease. Clin Pharmacokinet. 2018;57(3):315\u201333. https:\/\/doi.org\/10.1007\/s40262-017-0608-3.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2381_CR17","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40263-017-0434-z","volume":"31","author":"P Kocis","year":"2017","unstructured":"Kocis P, Tolar M, Yu J, Sinko W, Ray S, Blennow K, et al. Elucidating the A\u03b242 anti-aggregation mechanism of action of tramiprosate in Alzheimer\u2019s disease: integrating molecular analytical methods, pharmacokinetic and clinical data. CNS Drugs. 2017;31(6):495\u20139. https:\/\/doi.org\/10.1007\/s40263-017-0434-z.","journal-title":"CNS Drugs"},{"issue":"9","key":"2381_CR18","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40263-018-0554-0","volume":"32","author":"JA Hey","year":"2018","unstructured":"Hey JA, Kocis P, Hort J, Abushakra S, Power A, Vyhn\u00e1lek M, et al. Discovery and identification of an endogenous metabolite of tramiprosate and its prodrug ALZ-801 that inhibits beta amyloid oligomer formation in the human brain. CNS Drugs. 2018;32(9):849\u201361. https:\/\/doi.org\/10.1007\/s40263-018-0554-0.","journal-title":"CNS Drugs"},{"issue":"7","key":"2381_CR19","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40265-024-02067-8","volume":"84","author":"JA Hey","year":"2024","unstructured":"Hey JA, Abushakra S, Blennow K, Reiman EM, Hort J, Prins ND, et al. Effects of oral ALZ-801\/Valiltramiprosate on plasma biomarkers, brain hippocampal volume, and cognition: results of 2-year single arm, open label, phase 2 trial in APOE4 carriers with early Alzheimer\u2019s disease. Drugs. 2024;84(7):811\u201323. https:\/\/doi.org\/10.1007\/s40265-024-02067-8.","journal-title":"Drugs"},{"issue":"7","key":"2381_CR20","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-024-02068-7","volume":"84","author":"JA Hey","year":"2024","unstructured":"Hey JA, Yu JY, Abushakra S, Schaefer JF, Power A, Kesslak P, et al. Analysis of cerebrospinal fluid, plasma \u03b2-amyloid biomarkers, and cognition from a 2-year phase 2 trial evaluating oral ALZ-801\/Valiltramiprosate in APOE4 carriers with early Alzheimer\u2019s disease using quantitative systems pharmacology model. Drugs. 2024;84(7):825\u201339. https:\/\/doi.org\/10.1007\/s40265-024-02068-7.","journal-title":"Drugs"},{"issue":"11","key":"2381_CR21","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s40265-025-02250-5","volume":"85","author":"S Abushakra","year":"2025","unstructured":"Abushakra S, Power A, Watson D, Porsteinsson A, Sabbagh M, MacSweeney E, et al. Clinical efficacy, safety and imaging effects of oral valiltramiprosate in APOE\u03b54\/\u03b54 homozygotes with early Alzheimer\u2019s disease: results of the phase III, randomized, double-blind, placebo-controlled, 78-week APOLLOE4 trial. Drugs. 2025;85(11):1455\u201372. https:\/\/doi.org\/10.1007\/s40265-025-02250-5.","journal-title":"Drugs"},{"issue":"3","key":"2381_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12498","volume":"10","author":"S Abushakra","year":"2024","unstructured":"Abushakra S, Porsteinsson AP, Sabbagh M, Watson D, Power A, Liang E, et al. APOLLOE4 phase 3 study of oral ALZ-801\/Valiltramiprosate in APOE \u03b54\/\u03b54 homozygotes with early Alzheimer\u2019s disease: trial design and baseline characteristics. Alzheimers Dement Transl Res Clin Interv. 2024;10(3):e12498. https:\/\/doi.org\/10.1002\/trc2.12498.","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"issue":"3","key":"2381_CR23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40262-025-01482-8","volume":"64","author":"JA Hey","year":"2025","unstructured":"Hey JA, Yu JY, Abushakra S, Schaefer JF, Power A, Kesslak P, et al. Clinical pharmacokinetics of oral ALZ-801\/Valiltramiprosate in a 2-year phase 2 trial of APOE4 carriers with early Alzheimer\u2019s disease. Clin Pharmacokinet. 2025;64(3):407\u201324. https:\/\/doi.org\/10.1007\/s40262-025-01482-8.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"2381_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40263-025-01251-y","volume":"40","author":"S Abushakra","year":"2025","unstructured":"Abushakra S, Doraiswamy PM, Hey JA, Tosun D, Barkhof F, Barakos J, et al. Hippocampal atrophy on magnetic resonance imaging as a surrogate marker for clinical benefit and neurodegeneration in early symptomatic Alzheimer\u2019s disease: synthesis of evidence from observational and interventional trials. CNS Drugs. 2025;40(2):199\u2013214. https:\/\/doi.org\/10.1007\/s40263-025-01251-y.","journal-title":"CNS Drugs"},{"issue":"4","key":"2381_CR25","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1093\/brain\/awag001","volume":"149","author":"N Benina","year":"2026","unstructured":"Benina N, Buitrago L, De Simone FI, Radwan RR, Miller MC, Martin K, et al. Plasma pTau217\/b-amyloid 1\u201342 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology. Brain. 2026;149(4):1168\u201381. https:\/\/doi.org\/10.1093\/brain\/awag001.","journal-title":"Brain"},{"issue":"1","key":"2381_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"issue":"6","key":"2381_CR27","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"issue":"1","key":"2381_CR28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214441","volume":"106","author":"PCL Ferreira","year":"2026","unstructured":"Ferreira PCL, Bellaver B, Povala G, Bauer-Negrini G, Aguzzoli CS, Ferrari-Souza JP, et al. Evaluating plasma p-tau217 as an endpoint for Alzheimer disease clinical trials. Neurology. 2026;106(1):e214441. https:\/\/doi.org\/10.1212\/WNL.0000000000214441.","journal-title":"Neurology"},{"key":"2381_CR29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214441","author":"M Doraiswamy","year":"2026","unstructured":"Doraiswamy M, Schneider R. Response letter: evaluating plasma p-tau217 as an endpoint for Alzheimer disease clinical trials. Neurology. 2026. https:\/\/doi.org\/10.1212\/WNL.0000000000214441.","journal-title":"Neurology"},{"issue":"4","key":"2381_CR30","doi-asserted-by":"publisher","first-page":"823","DOI":"10.14283\/jpad.2024.134","volume":"11","author":"RA Rissman","year":"2024","unstructured":"Rissman RA, Donohue MC, Langford O, Raman R, Abdel-Latif S, Yaari R, et al. Longitudinal phospho-tau217 predicts amyloid positron emission tomography in asymptomatic Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2024;11(4):823\u201330. https:\/\/doi.org\/10.14283\/jpad.2024.134.","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"2381_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.70330","volume":"87","author":"K Biberoglu","year":"2026","unstructured":"Biberoglu K, Tacal O. Tramiprosate, the active agent of ALZ-801, modulates amyloidogenic APP processing and tau phosphorylation in a cellular model of Alzheimer\u2019s disease. Drug Dev Res. 2026;87(4):e70330. https:\/\/doi.org\/10.1002\/ddr.70330.","journal-title":"Drug Dev Res"},{"issue":"11","key":"2381_CR32","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1002\/alz.13026","volume":"19","author":"J Therriault","year":"2023","unstructured":"Therriault J, Servaes S, Tissot C, Rahmouni N, Ashton NJ, Benedet AL, et al. Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement. 2023;19(11):4967\u201377. https:\/\/doi.org\/10.1002\/alz.13026.","journal-title":"Alzheimers Dement"},{"issue":"10544","key":"2381_CR33","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/S0140-6736(26)00459-9","volume":"407","author":"JL Cummings","year":"2026","unstructured":"Cummings JL, Atri A, Sano M, Zetterberg H, Scheltens P, Knop FK, et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer\u2019s disease (EVOKE and EVOKE+): two phase 3, randomized, placebo-controlled trials. Lancet. 2026;407(10544):2167\u201379. https:\/\/doi.org\/10.1016\/S0140-6736(26)00459-9.","journal-title":"Lancet"},{"issue":"2","key":"2381_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14414","volume":"21","author":"T Bittner","year":"2025","unstructured":"Bittner T, Tonietto M, Klein G, Belusov A, Illiano V, Voyle N, et al. Biomarker treatment effects in two phase 3 trials of gantenerumab. Alzheimers Dement. 2025;21(2):e14414. https:\/\/doi.org\/10.1002\/alz.14414.","journal-title":"Alzheimers Dement"},{"key":"2381_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126355","volume":"22","author":"M Tolar","year":"2021","unstructured":"Tolar M, Hey J, Power A, Abushakra S. Neurotoxic soluble amyloid oligomers drive Alzheimer\u2019s pathogenesis and represent a clinically validated target for slowing disease progression. Int J Mol Sci. 2021;22:6355. https:\/\/doi.org\/10.3390\/ijms22126355.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2381_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052727","volume":"25","author":"M Tolar","year":"2024","unstructured":"Tolar M, Hey J, Power A, Abushakra S. The single toxin origin of Alzheimer\u2019s disease and other neurodegenerative disorders enables targeted approach to treatment and prevention. Int J Mol Sci. 2024;25(5):2727. https:\/\/doi.org\/10.3390\/ijms25052727.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2381_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-024-00690-w","volume":"4","author":"L Bl\u00f6meke","year":"2024","unstructured":"Bl\u00f6meke L, Rehn F, Pils M, Kraemer-Schulien V, Cousin A, Kutzsche J, et al. Blood-based quantification of A\u03b2 oligomers indicates impaired clearance from brain in ApoE \u03b54 positive subjects. Commun Med. 2024;4(1):262. https:\/\/doi.org\/10.1038\/s43856-024-00690-w.","journal-title":"Commun Med"},{"issue":"2","key":"2381_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12589","volume":"16","author":"L Bl\u00f6meke","year":"2024","unstructured":"Bl\u00f6meke L, Rehn F, Kraemer-Schulien V, Kutzsche J, Pils M, Bujnicki T, et al. A\u03b2 oligomers peak in early stages of Alzheimer\u2019s disease preceding tau pathology. Alzheimers Dement Diagn Assess Dis Monit. 2024;16(2):e12589. https:\/\/doi.org\/10.1002\/dad2.12589.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"issue":"8","key":"2381_CR39","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1007\/s00216-026-06349-w","volume":"418","author":"M Vlk","year":"2026","unstructured":"Vlk M, Muck A, Hey JA, Schaefer JF, Hub\u00e1lek M, Cva\u010dka J. Analysis of amyloid beta oligomers by cyclic ion mobility-mass spectrometry. Anal Bioanal Chem. 2026;418(8):2273\u201386. https:\/\/doi.org\/10.1007\/s00216-026-06349-w.","journal-title":"Anal Bioanal Chem"}],"updated-by":[{"DOI":"10.1007\/s40265-026-02407-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02381-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02381-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02381-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:01:47Z","timestamp":1792785707000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02381-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2381"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02381-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"21 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-026-02407-w","URL":"https:\/\/doi.org\/10.1007\/s40265-026-02407-w","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The APOLLOE4 trial was approved by Advarra Central IRB and by the required local university IRBs in the USA, and by country specific Ethics Committees in UK and EU. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The Phase 2 study protocol was approved by the ethics committees (EC) in the Netherlands and in Czech Republic. The study was conducted in accordance with the International Council for Harmonization (ICH) Guideline for Good Clinical Practice (GCP) and applicable local regulatory requirements.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All Phase 3 study subjects and their partners, caregivers, or legal representatives signed informed consent before participation in the trial. The Phase 2 study and informed consents were also approved by the Independent Ethics Committee at each study center, and all patients and\/or their legal representatives and study partners provided written informed consent.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data supporting findings of this study are available from Alzheon, Inc., but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the corresponding authors upon reasonable request and with permission of Alzheon, Inc.","order":5,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JA Hey, S Abushakra, A Power, E Ling, S Flint, E Hristova, P Kesslak, R McLaine, A Albayrak, JF Schaefer, JY Yu, L Tolar, and M Tolar are employees of Alzheon Inc., who received salary compensations, stocks and\/or stock options from Alzheon Inc. The AD experts (A Porsteinsson, M Sabbagh, PM Doraiswamy, FM Elahi and RA Rissman) received consulting fees, stocks, and\/or stock options from Alzheon Inc. and multiple other pharmaceutical companies developing CNS drugs, devices or diagnostic tests. The site investigators (D Watson, E MacSweeney, S Cohen and M Boada) received investigator fees for this study and multiple other AD and CNS trials from various global pharmaceutical companies.","order":6,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JA Hey, JY Yu, and L Tolar contributed to manuscript preparation. S Abushakra is the principal investigator of the NIH\/NIA grant for the APOLLOE4 trial. S Abushakra, A Power, E Liang, S Flint, JA Hey, and M Tolar designed the trial and oversaw its conduct, data analysis, data interpretation, and manuscript preparation. All other Alzheon employees contributed to one or more of the following: trial conduct and oversight, safety oversight, sample analyses, data analyses, and data interpretation. A Porsteinsson, M Sabbagh, PM Doraiswamy, FM Elahi, and RA Rissman were scientific advisors to Alzheon Inc. who contributed to the study design, data analysis, data interpretation, and critical review of the manuscript. D Watson, E McSweeney, S Cohen, and M Boada were trial investigators in the USA, UK, Canada, and Europe, respectively; they contributed to the trial conduct, safety discussions, data interpretation and manuscript review. All authors reviewed and approved the final submitted version of the manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}